<DOC>
	<DOCNO>NCT01229072</DOCNO>
	<brief_summary>The Heparin form complex plasma protein , antithrombin III ( ATIII ) , endogenous anticoagulant . This complex inhibit formation thrombin accelerate destruction . Moreover , heparin protease ATIII inactivate clot cascade , especially anti-activated factor X . The end result action inhibition biochemical training synthesis certain clot factor activator critical function genesis blood clot . Patients chronic renal failure ( CRF ) use treatment hemodialysis need system anticoagulation direct thrombin inhibitor / heparinóides prevent thrombosis . Based clinical study , control level plasma heparin patient CRF essential . Evidence clot APTT , TP , ACT proof activity anti-factor Xa use substrate protection patient hemodialysis .</brief_summary>
	<brief_title>Safe Use Heparin Sodium Laboratory Blausiegel Compared Liquemine ® Laboratory Roche Patients With Chronic Renal Failure .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Adults sex , regardless color social class ; Age 18 year ; Patients agree participate study sign free inform consent ( attach ) ; Insufficient patient chronic renal dialysis scheme ( 3 time per week ) ; Low Chronic Renal indication anticoagulant dialysis . Not agree term describe informed consent ; Patients sensitivity heparin sodium ; Volunteer search hypersensitivity benzyl alcohol ; Patients history bleed change blood clot aggravate terminate clinical picture , table gastric ulcer ; Patients history peptic ulcer ; Patients cancer etiology , possibility compromise function variable coagulation ; Patients period pregnancy postpartum ; Individuals genetic abnormality clotting system ; Patients polytraumatized ; Patients use glucocorticoid least 1 month ; Patients use anticoagulant ; Patients high rate bleeding ; Patients undergo surgery perform less 15 day risk formation hematomas site surgery ; Patients use drug affect hemostasis ; In addition , clinical characteristic medical criterion , interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Safety</keyword>
	<keyword>Non-inferiority</keyword>
</DOC>